Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Tender notice |
| Buyer: | MHRA |
| Main Category: | Services |
| Procurement Method: | Open procedure |
| Tender Status: |
| Open |
| Estimated Value (ex. VAT): | £10,000,000 |
| Estimated Value (inc. VAT): | £12,000,000 |
| Release Date: | 1 July 2026 |
| Application Deadline: | 6 August 2026 |
| Enquiry Deadline: | 21 July 2026 |
| Contract Start Date: | 15 October 2026 (Estimated) |
| Contract End Date: | 15 October 2029 (Estimated) |
| Contract Duration: | 3.1 years |
| Procurement ID (OCID): | ocds-h6vhtk-060643 |
| Notice Reference: | 061976-2026 |
All 2 notices for this procurement, oldest first.
Scientific Advice Framework
Medicines Licensing Assessor Services
Ready to bid on this contract?
BidWriter AI writes your tender response in minutes — import this contract in one click.
View Original Notice
Access the full notice on the official portal
| Call-off method: | Both: direct call-off and mini-competition |
| Maximum operators: | 12 |
The Medicines and Healthcare products Regulatory Agency is the regulator of medicines, medical devices and blood components for transfusion in the UK. MHRA carries out a wide range of activities to fulfil its role as a patient safety regulator. This includes carrying out assessments of the safety, quality and efficacy of medicines, assessing the safety of proposed clinical trials of medicines and medical devices, inspecting the premises of those manufacturing, supplying or distributing medicines and monitoring the ongoing safety of all medical products, taking swift action where necessary to prevent harm to patients. The MHRA also engages with companies within the regulated sector to provide specific, scientific advice on the development of products. The aim of such advice is to ensure the developer understands the requirements of the regulator, ensuring that the developer can provide the required information to support a properly informed assessment. With a wide range of critical deliverables, MHRA is seeking opportunities to add to its traditional in-house expertise through the establishment of additional sources of both capacity and capability. These will enable MHRA to deliver innovative, new and improved services at increased pace, safeguarding public health and supporting the growth of life sciences in the UK. MHRA is seeking suppliers with the capacity and capability to deliver assessments of complex clinical and non-clinical regulatory data and provide carefully evidenced judgements within an MHRA assessment and quality assurance framework. Such assessments may relate to marketing authorisation applications, clinical trial applications and a variety of other compliance activities. Deployment of supplier resources will be on a flexible basis to enable MHRA greater discretion in flexing established capacity as needed to support increased growth in UK life sciences through new and improved advice and support services. To achieve this ambition, MHRA wishes to establish a framework of specialist providers, which cover 3 Lots. Up to four suppliers, who meet the minimum criteria, may be awarded a place on each Lot. Lot 1: Pharmaceutical Assessment: Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document). Lot 2: Medical Assessment: Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document). Lot 3: Non-Clinical Assessment: Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).
Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document).
Contract period: 15 October 2026 → 15 October 2029
Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document).
Contract period: 15 October 2026 → 15 October 2029
Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).
Contract period: 15 October 2026 → 15 October 2029
Document pack· 1 file
Published contracts in the last 12 months
77
total contracts
£62.9m
total value
£1,906,758
average contract size
Typical categories
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
6 August 2026
36 days left
Estimated Value
£10,000,000
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →